primary antibodies against phosho-fak y397 (focal adhesion kinase (Cell Signaling Technology Inc)
Structured Review

Primary Antibodies Against Phosho Fak Y397 (Focal Adhesion Kinase, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies against phosho-fak y397 (focal adhesion kinase/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines"
Article Title: An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines
Journal: International Journal of Molecular Sciences
doi: 10.3390/ijms24065648
Figure Legend Snippet: Effect of cabozantinib on signal transduction in human RCC treatment-naïve 786-O/WT cells and following long-term treatment with sunitinib in human RCC 786-O/S cell lines. ( a ) Cell lysates (20 µg) obtained from wild-type 786-O/WT and 786-O/S cells treated (+) with 12 µM of cabozantinib (Cbz) or untreated (−) with DMSO 0.1% at four time points were analyzed with an immunoblotting assay with specific antibodies for indicated proteins. GAPDH expression was chosen as the loading control for the samples. The optical density (OD) of the area of each band was quantified with ImageJ 1.52a software and normalized to that of GAPDH. Numbers below each line represent the fold changes of the target proteins, which were obtained by dividing the normalized expression from each lane by the normalized expression of the relative untreated controls (set as 1). ( b ) Kinetics of AKT (S473 and T308) in 786-O/WT and 786-O/S cells following treatment with cabozantinib (+Cbz) and untreated control (CTR) at indicated time points. The optical density (OD) of the area of each band of phosphorylated and total AKT was quantified with ImageJ 1.52a software and normalized to that of GAPDH. Phosphorylation kinesis adjusted for AKT (S473/tot AKT and T308/tot AKT). ( c ) Comparative expression levels (fold change) of proteins P-Src, P-FAK and P-S6K between cabozantinib-treated and untreated samples. The relative protein expression (densitometry normalized to the loading control) of each cabozantinib-treated sample was compared with the corresponding DMSO-treated (control, CTR) samples (set as 1) to assess the fold change between the two experimental conditions. Representative immunoblotting image and relative quantification. Full-length blots of independent duplicates are presented in . The figure was generated with Inkscape (version 1.0.2, RRID: SCR_014479).
Techniques Used: Transduction, Western Blot, Expressing, Software, Generated

